Mechanism-linked potency assays drive gene therapy success
VectorBuilder’s Alan Griffith explains the value of MoA-reflective potency assays for gene therapy development and the benefits of working with assay specialists like Svar Life Science
Clinical Diagnostics
The global #CLINICAL24 2025 conversation has begun! Tell us your daily challenges and let's explore the solutions together
Explore topics
Biopharmaceuticals
Explore insights on gene, cell & regenerative therapies driving personalized, next-gen healthcare
Explore feature
Life Sciences
Discover how multiomics is transforming biomedical research and driving the latest innovations in the field
Explore feature
